.png){kind=icon}
.png){kind=icon}
Return
The novel polymyxin analogue SPR206 exhibits higher activity than colistin against both colistin-susceptible and colistin-resistant strains of Acinetobacter baumannii
.png){kind=icon}
OA
AI
M
A
P
A
G
R
I
J
J
G
A
DOI：10.1128/aac.01940-24.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Colistin resistance is increasing globally and complicates treatments of A. baumannii infections. The next-generation polymyxin SPR206 shows potent activity against multidrug-resistant Gram-negative pathogens with low toxicity. SPR206 exhibited higher activity against colistin-susceptible and colistin-resistant strains (MIC50/MIC90 = 0.12/0.25 mg/L), and resistance was only detected in 1/118 strains (MIC >= 4 mg/L). Mutations in pmrCAB, linked to colistin resistance, do not seem to confer resistance to the novel polymyxin, which retains a high level of activity.
Keywords:
antimicrobial resistance
colistin
SPR206
Acinetobacter baumannii
Journal
IF:
4.5
Papers:
2.3W
Citations:
6.2W
Organization
Cited Papers